10 Biggest Price Target Changes For Monday
Barclays reduced the price target for The Walt Disney Company (NYSE: DIS) from $210 to $175. Disney shares fell 1.6% to $173.60 in pre-market trading.
Raymond James Maintains Strong Buy on Ocular Therapeutix, Raises Price Target to $29
Raymond James analyst Dane Leone maintains Ocular Therapeutix (NASDAQ:OCUL) with a Strong Buy and raises the price target from $25 to $29.
HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Raises Price Target to $18
HC Wainwright & Co. analyst Yi Chen maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $17 to $18.
Why Are Ocular Therapeutix Shares Trading Higher Today?
The FDA has approved Ocular Therapeutix Inc’s (NASDAQ:OCUL) supplemental application to broaden the Dextenza label. The approval now adds an indication…
Ocular Therapeutix Announces FDA Approval Of Supplemental New Drug Application For DEXTENZA 0.4 mg For Intracanalicular Use For Treatment Of Ocular Itching Associated With Allergic Conjunctivitis
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the U.S.
Ocular Therapeutix Shares Move Higher; Traders Circulate Oct. 7 FDA Approval For Co’s Dextenza
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208742
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned.